LFSTLifeStance Health Group, Inc.

Healthcare

$12.95+157% 1Y

$12.95

$4.8152 weeks$13.39

Is the price fair?

Fair

Neither cheap nor expensive: modest expectations priced in, but rich vs its sector.

1 good, 1 to watch, 1 without data

What the price assumes~+10% a year

Priced for ~10% a year FCF growth. The price demands less than its three-year revenue growth of 18% a year, expectations look modest.

Vs sector (EV/EBIT)63.7×

Sector median 25.1× across 135 covered peers. EV/EBIT counts debt as part of the price, so a cash-rich and a borrowed company can be compared on the same footing.

All from derived, as of Jun 30, 2026.

Against the whole market›

Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.

P/E (valuation)bottom 5% of the market

FCF yieldbehind 68% of the market

Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.

What LFST's price assumes

LifeStance Health Group, Inc. trades at 99.6× earnings against 20.2× for the median Medical Care Facilities name, more expensive than its own group.

99.6

Trailing P/E · Medical Care Facilities median 20.2 · 4.93× the median: the market pays up for this one

Price / sales: 3.12
Price / sales · today's price, trailing year to Jun 30, 2026
Free cash flow yield: 3.5%
Free cash flow yield · Medical Care Facilities median 6.0%
Growth the price implies: +10%
Growth the price implies · The price pays for +10% free cash flow growth a year for a decade; revenue has grown 18% a year over the last three.